GlassScriptPhysician profile
John F Walling
NPI 1073579512
$2,793.69
in general payments reported to CMS, 2019-2025
26 companies · $529 in 2025
The $529 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $143 · 2021: $85.18 · 2022: $166 · 2023: $875 · 2024: $700 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.95 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.72 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Pfizer INC. | $248.22 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.40 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $187.38 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $157.82 | 2019-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $133.28 | 2023-2025 | Dupixent |
| Boston Scientific Corporation | $128.98 | 2024 | Exalt Model D |
| Gilead Sciences, INC. | $102.98 | 2023-2025 | |
| Lilly USA, LLC | $88.99 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $71.78 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $68.32 | 2023 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $65.43 | 2021-2023 | |
| Qol Medical, LLC | $63.80 | 2020-2024 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $50.91 | 2023-2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $48.38 | 2022-2025 | Ocaliva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $47.65 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $44.50 | 2019-2023 | Dificid |
| Ipsen Biopharmaceuticals, INC | $38.80 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $36.55 | 2023 | Linzess |
| Olympus America INC. | $22.92 | 2019 | |
| Amgen INC. | $21.78 | 2023 | Amjevita, Avsola |
| Alnylam Pharmaceuticals INC. | $21.58 | 2023 | Givlaari |
| Genzyme Corporation | $21.48 | 2025 | |
| Ferring Pharmaceuticals INC. | $16.75 | 2023 | Rebyota |
| Celltrion USA INC. | $16.63 | 2025 | Vegzelma |
| Mylan Institutional INC. | $13.66 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Walling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.